|Enlivex Therapeutics Ltd., of Ness Ziona, Israel||Allocetra||Immunotherapy||Severe sepsis||Acute Physiology and Chronic Health Evaluation score of Allocetra-treated group was 12.3, and corresponding probability of mortality of at least 1 patient in that group was predicted at 85% based on hospital’s ICU staff’s clinical assessment of each patient’s overall condition at admission; no Allocetra-treated patients died during the 28-day study period, as compared to 27% 28-day mortality in the matched controls group|
|Graybug Vision Inc., of Redwood City, Calif.||GB-102||Small-molecule multiple receptor tyrosine kinase inhibitor, sunitinib malate, in microparticle formulation||Anti-VEGF-responsive wet age-related macular degeneration||Enrollment closed early|
|Ideaya Biosciences Inc., of South San Francisco||IDE-196||Protein kinase C inhibitor||Metastatic uveal melanoma and GNAQ/GNA11 hotspot mutation solid tumors||Selected monotherapy dose of 400 mg twice daily (with 1-week 200-mg twice-daily run-in) and achieved first patient in for GNAQ/GNA11 non-MUM basket trial|
|Sellas Life Sciences Group Inc., of New York||Nelipepimut-S in combination with granulocyte-macrophage colony-stimulating factor||Cancer vaccine||Ductal carcinoma in situ of the breast||Drug shown capable of inducing an antigen-specific antitumor immune response in DCIS patients even after a single vaccination; trial enrolled patients who were HLA-A2+ or A3+ positive, express HER2 at IHC 1+, 2+, or 3+ levels, and are pre- or post-menopausal|
|Vivoryon Therapeutics AG, of Halle, Germany||PQ-912||Small-molecule inhibitor of glutaminyl cyclase||Early Alzheimer's disease||Trial has added exploratory parameters selected with the rationale of advancing less invasive diagnostic technologies, including Winterlight Labs speech assessment, the use of EEG to test neuronal network activity and connectivity, as well as a set of blood-based biomarkers|
|Addex Therapeutics Ltd., of Geneva||Dipraglurant||Metabotropic glutamate receptor 5 antagonist||Parkinson’s disease||Will delay start of registrational efficacy and safety study (Study 301) in levodopa-induced dyskinesia|
|Iveric Bio Inc.||Zimura (avacincaptad pegol)||Complement C5a receptor antagonist; complement cascade inhibitor||Dry age-related macular degeneration||Company decided to delay initiation of enrollment of patients in the second pivotal trial|
For more information about individual companies and/or products, see Cortellis.